Purpose : To investigate the pharmacologic modulation of motor task-dependent physiologic responses by antiplatelet agent, clopidogrel, during hand motor tasks in healthy subjects.
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Many lines of evidence suggest that cerebral activity can be modulated by pharmacologic compound and that fMRI sensitivity is high enough to evidence such changes (1) (2) (3) . Loubinoux et al. demonstrated that cerebral motor activity can be modulated by fluoxetine, an inhibitor of serotonin reuptake, or fenozolone, an amphetamine-like drug during hand motor task in healthy subjects (4) . The action of both drugs on motor cortices, SMA, and cerebellum suggests a facilitatory or stimulating function of the monoaminergic systems on motor activity. Also, the excitatory effect of both noradrenaline and dopamine on motor behavior demonstrated in animal and clinical studies (5, 6) . Pharmacologic modulation of motor activity has potential clinical importance because these drugs may facilitate motor recovery in poststroke patients undergoing motor reorganization. Although pharmacologic modulation of noradrenaline, dopamine, and serotonin on motor behavior was demonstrated in healthy subjects and clinical studies, the effect of antiplatelet compound on motor activity is not discussed.
An antiplatelet drug is a member of a class of drug that decreases platelet aggregation and inhibits thrombus formation (7, 8) . They are effective in the arterial circulation, where anticoagulants have little effect and are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease. Clopidogrel is a potent oral antiplatelet agent often used in the treatment of coronary artery disease, peripheral vascular disease, and cerebrovascular disease (9) . The mechanism of action of clopidogrel is irreversible blockade of the adenosine diphosphate (ADP) receptor on platelet cell membranes (10) . This receptor is named P2Y12 and is important in platelet aggregation, the cross-linking of platelets by fibrin. The blockade of this receptor inhibits platelet aggregation by blocking activation of the glycoprotein Iib/IIIa pathway.
In this study, the pharmacologic modulation of motor task-dependent physiologic responses by antiplatelet agent, clopidogrel, during hand motor tasks were investigated in healthy subjects. Since antiplatelet therapy is often used to improve brain perfusion, antiplatelet agent is potentially expected to be effective for preventing or recovering ischemic diseases such as stroke. Furthermore, the main symptom of stroke is motor weakness. Therefore, the motor task seems to be most relevant fMRI task to investigate pharmacologic modulation by clopidogrel. Effects on cerebral motor activity of high dose and steady state of clopidogrel were assessed separately by fMRI. Drug effects were assessed in three sessions in which the same subjects repeated the same motor task before and after drug adminstration. Each session is separated at least by 24 hours to avoid habituation effects which may take place in pharmacologic studies.
Subjects
Ten healthy, right-handed subjects (10 males; mean age, 26 5 years; range 24 to 28 years) participated in this study. Since there was no female volunteer, only male subjects were recruited in this study. None of the subjects had a previous history of neurological or cardiac disease or symptoms. After detailed explanation of the study design and potential risks, all subjects gave written informed consent. All study protocols were approved by the local Internal Review Board.
Motor Paradigm Design
The subjects were examined with their eyes closed and were secured firmly with the forearm in pronation using an immobilizing frame to minimize body movement effects. For the motor task paradigm, finger flexion-extension movements were performed at a frequency of 1 Hz for stimulation over a repeated cycle of 15 seconds of control and 15 seconds of stimulation. Each task paradigm of alternating controlstimulation (30 seconds) was repeated three times (three blocks). Total acquisition time was 1 minute 30 seconds. For the same subjects, the fMRI session was repeated three times: one (day 0) before drug administration, one (day 1) after high dose drug administration (20 mg/50 kg clopidogrel), and one (day 6) after reaching drug steady state. The fMRI scans were performed at the peak plasma concentrations for high dose session.
Functional Magnetic resonance imaging
Blood oxygenation level dependent (BOLD) contrast was collected for each subject using a 3.0 T VHi (GE Healthcare, Milwakee, USA) scanner equipped with a transmit-receive body coil and a commercial eightelement head coil array. T2*-weighted echo planar imaging was used for fMRI acquisition. The following acquisition parameters were used in the fMRI protocol: echo time (TE) = 40 ms, repetition time (TR) = 2000 ms, field of view (FOV) = 22 cm, acquisition matrix = 64 ×64. Using a midsagittal scout image, 24 contiguous axial slices with 4 mm thickness were placed along the anterior-posterior commissure (AC-PC) plane covering the entire brain. The first three acquisitions were discarded due to T1-saturation effects. 3-D T1-weighted anatomical scan was obtained for structural reference.
Image Analysis
The image processing and statistical analyses were carried out using MATLAB v. 7.2(The Mathworks Inc., Natick, MA) and SPM2 (SPM; Wellcome Department of Imaging Neuroscience, London, UK; online at http://www.fil.ion.ucl. ac.uk) (11) . The functional images were corrected for sequential slice timing, and all images were realigned to the first image to correct
MATERIALS AND METHODS
for head movement between scans. The realigned images were then mean-adjusted by proportional scaling and spatially normalized into standard stereotactic space to fit a Montreal Neurological Institute template based on the standard stereotaxic coordinate system (12, 13) . For group analysis, the contrast images from the analysis of the individual subjects were analyzed by one-sample t-tests, thereby generating a random-effects model, allowing inference to the general population. A statistical threshold was assessed based on the spatial extent of the contiguous activity (p < 0.05 with correction for multiple comparisons with 16-contiguous voxel size). Clusters of fewer than 16 voxels were ignored. Finally, the resulting activation maps were created and displayed by projections onto the anatomically standardized mean T1 image of all subjects to identify the anatomical correlates of the activity.
Compared to the base-line activity without drug administration, the second-level analysis, which corrected for multiple comparisons (p < 0.05), for right hand motor task revealed significant increases in the extent of activation in the contralateral motor cortex including primary motor area (M1) after drug administration (Fig. 1) . The number of activated voxels in motor cortex (precentral and postcentral gyrus) was 173 without drug administration and the number increased as 1049 for high dose condition and 673 for steady-state condition respectively. However, there was no significant difference in the magnitude of BOLD signal change in terms of peak T value.
Whole-brain, voxel-by-voxel analyses revealed one additional motor-related region that was activated during drug sessions (day 1 and 6) with the administration of clopidogrel. This region was located in the supplemenrary motor area (SMA). In addition, the other areas, which showed significant activation after clopidogrel administration, were cerebellum, superior temporal gyrus, and middle frontal gyrus (Table 1) . Comparison between steady-state (day 6) and high dose condition (day 1) showed that the activations of motor cortex and SMA were more extended in high dose condition. It was also noticed that cerebellum activity was more significant both in extent (activated voxels = 1486) and magnitude (peak T = 17.45) in high dose condition.
In the present study, the effects of clopidogrel during motor task were investigated. The findings indicate that pharmacologically induced motor activity produced a regionally specific alteration in the pattern
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Pharmacological fMRI on Motor Function � Yongmin Chang of fMRI activation during high dose (day 1) and steady-state (day 6) sessions. An increase in both the extent and magnitude of activation was observed primarily in the motor cortex and SMA. To exclude the possibility that the observed pharmacological modulation on motor activity is within false positive error (type I), group analysis with multiple comparison correction was introduced. In fMRI studies, data analysis is usually done voxel-wise with all statistical tests conducted separately and simultaneously. Although these voxel-by-voxel tests increase the precision of the conclusions in terms of cluster size, a family of statistical tests suffer at least type I error (false positive), which is greater than that of an error on an individual test (14, 15) . Therefore, it was adapted a policy that the observed neural activation is not by chance but really related to the pharmacological effect of clopidogrel even though there is a chance to miss some voxels with true activation (false negative).
Although there were previous neuroimaging studies that have shown regional alterations in activation associated with pharmacologic manipulation (16, 17) , the current findings are the first demonstration of the cerebral pattern induced by an action of antiplatelet drug such as clopidogrel on motor activity. Clopidogrel induced an enhanced activation of primary motor and SMA at the concentrations used in this study by suggesting the pharmacological role in motor control. Moreover, in this study, it was not observed statistically significant difference in magnitude and extent of activation between high dose (day 1) and steady-state (day 6) sessions. The enhanced motor performance and efficiency of information processing in simple motor task has been demonstrated after the administration of fluvoxamine, the inhibitor of serotonin reuptake (18) .
For the interpretation of pharmacologic modulation of clopidogrel on motor activity, there seem to be two possibilities. One possibility depends on the global increase in the cerebral perfusion. Tokumaru et al demonstrated a marked improvement in brain perfusion after treatment with an antiplatelet agent (8) . In their study, using brain single photon emission (19, 20) , the antiplatelet effect of clopodogrel therefore modulates the extent and the magnitude of BOLD signal. However, on this explanation, further study is necessary to investigate whether global change in the water diffusion produced not only an increase in baseline BOLD signal but also an addictive increase of BOLD response. Finally, it is necessary to address limitation of this study. The current study did not include placebo session. In pharmacological study, the placebo session might have an importance because it presumably reflects psychological effect on the fMRI activation. That is, without placebo session, it is difficult to rule out that the observed BOLD activation is not from psychological effect.
In conclusion, the current study demonstrated, for the first time, that cerebral motor activity can be modulated by clopidogrel in healthy subjects and that fMRI is highly senstive to evidence such changes. these results showed that clopidogrel induced profound changes in the primary motor cortex and SMA. 
